Plasma is a composite mixture of more than 700 proteins and other substances which are vital for the smooth functioning of the human body. Plasma is the liquid component of blood, constituting around 50% of the total blood volume. Plasma in itself is approximately 90% water, with the remaining 10% comprising of proteins, minerals, clotting factors, hormones, and immunoglobins. Plasma is the raw material for the extraction of various proteins which are used for their therapeutic values. Plasma proteins cannot be manufactured rather the same are obtained or collected from a large pool of donors. With the swift progression in the field of biomedical/healthcare technology, companies operating in the healthcare/pharmaceutical/therapeutic industry are now surmounting in the respective realm. Also, on account of the escalating incidences of health related issues originating due to changing lifestyle and continuously changing surroundings, blood plasma industry’s growth is augmented. In order to address the unmet medical needs related to blood disorders, autoimmune diseases and liver function impairment among others, associated companies are coming up with novel and improved treatment options like IVIG, albumin, clotting factors etc. which are derived from human blood plasma. The blood plasma industry is highly regulated to ensure the safety of collected plasma and protect donors. The market is characterized by fast pace developments in the clinical technology and testing methodology. This report elicits the global blood plasma market with focus on segmental markets like IVIG, albumin and hemophilia market. Also the regions including the US and China are covered. Moreover, market dynamics like the key trends, industry developments, growth drivers and challenges are analyzed in detail. Furthermore, the competitive landscape of the industry is highlighted. The rivalry prevalent in the global blood plasma market is quite fierce with numerous local and global players contenting for the market share. On the global front, the key players are Baxter, CSL, Grifols and Octapharma.

1. View Report Details
Global Blood Plasma Market
-------------------------------------------
2013

2. View Report Details
Executive Summary
Plasma is a composite mixture of more than 700 proteins and other substances which are vital for the smooth functioning
of the human body. Plasma is the liquid component of blood, constituting around 50% of the total blood volume. Plasma in
itself is approximately 90% water, with the remaining 10% comprising of proteins, minerals, clotting factors, hormones, and
immunoglobins. Plasma is the raw material for the extraction of various proteins which are used for their therapeutic
values. Plasma proteins cannot be manufactured rather the same are obtained or collected from a large pool of donors.
With the swift progression in the field of biomedical/healthcare technology, companies operating in the
healthcare/pharmaceutical/therapeutic industry are now surmounting in the respective realm. Also, on account of the
escalating incidences of health related issues originating due to changing lifestyle and continuously changing
surroundings, blood plasma industry’s growth is augmented. In order to address the unmet medical needs related to blood
disorders, autoimmune diseases and liver function impairment among others, associated companies are coming up with
novel and improved treatment options like IVIG, albumin, clotting factors etc. which are derived from human blood plasma.
The blood plasma industry is highly regulated to ensure the safety of collected plasma and protect donors. The market is
characterized by fast pace developments in the clinical technology and testing methodology. This report elicits the global
blood plasma market with focus on segmental markets like IVIG, albumin and hemophilia market. Also the regions
including the US and China are covered. Moreover, market dynamics like the key trends, industry developments, growth
drivers and challenges are analyzed in detail.
Furthermore, the competitive landscape of the industry is highlighted. The rivalry prevalent in the global blood plasma
market is quite fierce with numerous local and global players contenting for the market share. On the global front, the key
players are Baxter, CSL, Grifols and Octapharma.

3. The normal composition of human blood is: Plasma, Red Blood Cells (RBC), White Blood Cells (WBC) and
Platelets…
Global Blood Plasma Market (2000-2011) The global blood plasma market was valued at US$.......billion in
2010, and reached US$....... billion in 2011, depicting an increase
of ……….% approximately. The recorded CAGR over the cited
2011 period was …….%.
2010
In terms of products, in 2011, the global blood plasma market
2009
was dominated by IVIGs or IGs with a significant share of ……..%
2008
followed by FVIII with …….% share. FIX and albumin constituted
2007 ……% share each.
2006
2005 The plasma derivatives sales in the US stood at US$....... billion
2004 in 2011, witnessing an increase of …..% approximately over the
2003 value of US$......... billion in 2010.
2002 The manufacturing cost structure of plasma fractionation is such
2001 that the major portion of the cost, approximately …..%, is
2000 constituted by plasma product.
US$ Billion
Plasma Derivative Sales in the US (2005-2011)
Global Plasma Market Share by Product (2011)
US$ Billion
2005 2006 2007 2008 2009 2010 2011
IG Factor VIII Factor IX Albumin Other Products

4. Plasma is the raw material for the extraction of various proteins. It can be divided into two categories
depending on how it is obtained viz. Source plasma and Recovered plasma...
Global IVIG Market Size (2004-2011)  As of 2011, the global sales of immunoglobulins stood at US$......
billion, registering a modest growth of …….% over the value of 2010.
For the period of 7 years spanning from 2004 to 2011, the global IVIG
market recorded an impressive CAGR of …………%.
 In terms of IVIG market size by volume, the US accounted for the
maximum share with ……..tonnes of IVIG, followed by the EU with
US$ Billion
……….tonnes of contribution in the global IVIG market as of 2011. In
terms of value, the U.S. market was worth ……..billion approximately
in 2011.
 The IVIG market in the US stood at US$............billion in 2011,
recording an increase of nearly ……..% over US$......... billion worth
sales generated in 2010. The CAGR recorded over the cited period
was ……..%.
2004 2005 2006 2007 2008 2009 2010 2011
Sales of IVIG in the US (2001-2011)
IVIG Market Volume by Region (2005, 2008 and 2011)
)
US$ Billion
Tonnes
2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
2005 2008 2011
USA EU RoW

5. In frozen condition, plasma can keep for up to 10 years, making it an extremely stable blood product.
Also, it can be packaged in dried form for reconstitution…
Global Plasma Market Share by Company (2011)
Global Hemophilia Treatment Market Revenues (2006-2012)
2012
2011
2010
2009
2008
2007
Grifols CSL
2006 Baxter Octapharma
Others- for profit Others- for non profit
US$ Billion
Albumin Market Size of the US and China The global hemophilia treatment market revenues has been moving on an
aggressive growth path, registering an increase of US$........billion to
US$........billion by 2012 as compared to US$............ billion in 2006.
As of October 2012, the albumin market of China was worth US$…….
million while the same in the US was worth US$........million only.
As of 2011, the global plasma market was led by Grifols with 20% share,
US$ Million
followed by CSL and Baxter with shares worth ……% and …..%,
respectively. Octapharma accounted for ………% share in the same.
The opportunity for global blood plasma market is anticipated to be US$......
billion for the year 2012. The respective market is poised to record a growth
of ……% in 2012 as compared to the value of US$.......billion in 2011. The
global blood plasma market is projected to grow at a CAGR of …….% over
the period of three years spanning from 2012 to 2015 and estimated to
reach US$.......... billion by the end of 2015.
USA China
Note: Market attractiveness is inverse of penetration. Low penetration means high attractiveness and vice-versa

6. Table of Contents List of Charts & Tables
1. Overview List of Charts
1.1 Components of Blood Plasma Plasma Extraction from Donated Blood (Recovered Plasma)
1.2 Functions of Blood Plasma Plasmapheresis (Source Plasma)
1.3 Collection and Extraction of Plasma Global Blood Plasma Market (2000-2011)
Global Plasma Market Share by Product (2011)
1.3.1 Plasma Collection Manufacturing Cost Split for Plasma Fractionation (September 2011)
1.3.2 Plasma Extraction Plasma Derivative Sales in the US (2005-2011)
1.3.3 Plasma Fractionation Yield US Source Plasma Collections (2007-2012E)
1.3.4 Plasma Usage Global IVIG Market Size (2004-2011)
Global IVIG Demand and Supply (2007-2012E)
2. Blood Plasma Market Structure IVIG Market Volume by Region (2005, 2008 and 2011)
Global IVIG Market Share by Geography (2011)
2.1 Global Blood Plasma Market IVIG Use by Indication
-Market Value Sales of IVIG in the US (2001-2011)
-Market Segments Global Hemophilia Treatment Market Revenues (2006-2012)
Global FVIII Market (2011)
2.1.1 Plasma Industry Cost Structure Global FIX Market (2011)
2.1.2 Plasma Market of the US Annual Global Sales of NovoSeven (2007-2011)
Monthly Distribution of FVIII in the US (January 2011-September 2012)
2.2 Global IVIG Market Albumin Market Size of the US and China
-Market Value Albumin Price across US and China
-Demand & Supply China’s Plasma Protein Market Growth (October 2012)
-Breakdown by Region Monthly Distribution of Albumin 25% in the US (January 2011-Sptember
2012)
2.2.1 IVIG Market of the US Monthly Distribution of Albumin 25% in the US (January 2011-Sptember
2012)
2.3 Global Hemophilia Market Licensed Plasma Centers in the US and their profitability (FY06-FY11)
-Hemophilia A A1PI Statistics of North America and EU
-Hemophilia B Per Capita Usage of FVIII in Developed Countries
Per Capita Usage of FVIII in Developing Countries
2.3.1 FVIII Market of the US Per Capita FIX Usage in Developed Economies
Per Capita FIX Usage in Emerging Economies
2.4 Albumin Market Global Healthcare Spending (2005-2015E)
Global Spending on Medicines (2006-2016E)
2.4.1 Albumin Market of China and the US Global Spending on Medicine Share by Region (2006-2016E)
3. Market Dynamics
3.1 Key Trends

7. 3.1.1 Kinetics of Plasma-collection Industry
List of Charts
3.1.2 Reimbursement
3.1.3 Growing Penetration of rFVIII Products in Emerging Markets
The US Spending on Medicine (2007-2016E)
– Opportunity for Manufacturers
Japan’s Spending on Medicine (2007-2016E)
3.1.4 A1PI Deficiency- Confined to Prevention only
Biotechnology Therapeutics Under Development (2011)
Global Ageing Population (2005-2013F)
3.2 Industry Developments
Global Male Population (2005-2014F)
Global GDP (2001-2011)
3.2.1 Improved Biological Molecule Formulations
World GDP per Capita (2005-2011)
3.2.2 Baxter’s Phase I Clinical Trial of Treatment for Hemophilia A
Global Plasma Market Share by Company (2011)
Aligned PCCs vs. independent PCCs Share in the US (2011)
3.3 Growth Drivers
Europe’s IVIG Market Share (2011)
North America’s IVIG Market Share (2011)
3.3.1 Increasing New Patient Registration for Hemophilia
US IVIG Market (2011)
Treatment
US Albumin Market Share (2011)
3.3.2 Increased Usage of Plasma Derived Products
China’s Albumin Market (2011-12)
3.3.3 Rising Healthcare Expenditure
Product Rivalry in the US (2011)
3.3.4 Higher Spending on Medicines
Baxter’s Revenue by Business Segments (2011)
3.3.5 Rising Demand for Better Healthcare Options
Baxter’s Revenues and Net Income (2008-2011)
3.3.6 Launch of NMEs (New Molecular Entities)
Grifols Revenue Share by Business Segments (2011)
3.3.7 Growing Ageing Population (+60 Years)
Grifols’ Revenues & Profits (2008-2011)
3.3.8 Rising Male Population
CSL’s Revenue Share by Major Products (2011-12)
3.3.9 Ameliorating Economic Conditions
CSL’s Revenues and Net Profit (2008/09-2011/12)
Octapharma’s Net Sales and Net Profit (2008-2011)
3.4 Challenges
Global Blood Plasma Market Forecast (2009-2015F)
3.4.1 Increasing regulation in the plasma-collection industry
List of Tables
3.4.2 Escalating Price Pressure
3.4.3 Constrained Plasma Fractionation Capacity
Constituents of Blood Plasma
3.4.4 Misdiagnosis of the Disease
Recovered plasma vs. Source plasma
Output per Liter of Plasma
4. Competitive Landscape
Breakdown of US IVIG usage by Patient Share & Volume Share by Indication
Breakdown of US SCIG and IVIG Usage by Volume Share (FY11)
4.1 Blood Plasma Market Rivalry
US Centre for Medicare and Medicaid (CMS) Reimbursement
4.2 Plasma Derivatives Market Contention
Conversion to Recombinant Factor VIII Products in Selected Countries (2010)
A1PI Products
4.2.1 Immunoglobulins
Long Acting FIX & FVIII under Late-Stage Development
-IVIG Market of Europe
-IVIG Market of North America
-IVIG Market of the US
4.2.2 Albumin Market
-Albumin Market of the US

8. -Albumin Market of China
List of Tables
4.2.3 Other Products
Extended Half Life rFVIII Agents
5. Company Profiles
Extended Half Life rFIX Agents
New Patient Registrations in Worldwide Bleeding Disorders Market (2008-
5.1 Baxter International Inc.
2013E)
5.1.1 Business Overview
Patients Worldwide Waiting for Better Treatment Options (2011)
5.1.2 Financial Overview
Global Availability of NMEs (2011)
5.1.3 Business Strategies
IVIG Product Characteristics
-Focus on Investment in R&D
Dependent & Independent Variables (2007-2011)
-Growth through Sustainable Development
Correlation Matrix
Regression Coefficients Output
5.2 Grifols
5.2.1 Business Overview
5.2.2 Financial Overview
5.2.3 Business Strategies
-Expansion in Other Geographic Regions
-Growth through Mergers and Acquisitions
5.3 CSL Limited
5.3.1 Business Overview
5.3.2 Financial Overview
5.3.3 Business Strategies
-Focus on R&D
-Expanding Product Portfolio
5.4 Octapharma
5.4.1 Business Overview
5.4.2 Financial Overview
5.4.3 Business Strategies
-Focus on Innovation
-Expansion of Production Facilities
6. Market Outlook
6.1 Market Forecast
6.2 Forecast Methodology
6.2.1 Dependent and Independent Variables
6.2.2 Correlation Analysis
6.2.3 Regression Analysis

9. Contact Us:
View Report Details
These are abridged and sanitized sample pages from the comprehensive report on the “Global Blood Plasma Market”. To know
more about this report or for any customized research requirement, please contact the following:
Koncept Analytics
CS-36, Second Floor, Ansal Plaza
Vaishali, Ghaziabad,
U.P. – 201010
Vikas Gupta T. +91-120-4130959
BD Manager C: +91-9811715635
vikas@konceptanalytics.com
www.konceptanalytics.com